CADTH | Evidence Driven
CADTH | Evidence Driven

Imfinzi for Non-Small Cell Lung Cancer – Details

Details

Files
Generic Name:
Durvalumab
Project Status:
Complete
Therapeutic Area:
Unresectable Non-Small Cell Lung Cancer (NSCLC)
Manufacturer:
AstraZeneca Canada
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0131-000
NOC Status at Filing:
Post NOC
Strength:
50 mg
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) following curative intent platinum-based chemoradiation therapy, for up to a maximum of 12 months
Sponsor:
AstraZeneca Canada
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Imfinzi for Non-Small Cell Lung Cancer – pERC Final Recommendation Final Recommendation May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – Final Economic Guidance Report Guidance Reports May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – Final Clinical Guidance Report Guidance Reports May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – pERC Initial Recommendation Initial Recommendation May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – PAG Feedback on Initial Recommendation Feedback May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – Manufacturer Feedback on Initial Recommendation Feedback May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – Clinician Feedback on Initial Recommendation Feedback May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – Patient Advocacy Group COI Declarations COI Declarations May 3, 2019 View PDF
Imfinzi for Non-Small Cell Lung Cancer – Clinician COI Declarations COI Declarations May 3, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : May 21, 2019